The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease.

Clin Kidney J · 2025 · PMC11914879 · PMID 40104551

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Using this approach, six of seven (86%) treated patients with MN experienced PR, two of them experiencing CR and one non-responder exhibiting a decreasing trend in proteinuria.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.